SOBHA.NSE

Sobha Ltd.

Sobha Ltd plans to launch 15 projects worth nearly Rs 22,000 crore over the next 18 months, spanning 16.7 million sq ft across residential and commercial spaces in cities including Bengaluru, Mumbai, Delhi-NCR, and Chennai.

Indian homebuilder Sobha reported a more than doubled second-quarter profit, driven by high prices and sustained demand for premium apartments. Revenues surged 50.7% to 14.08 billion rupees, with sales rising 61% to 19.03 billion rupees. Analysts anticipate continued healthy demand for residential apartments, particularly from credible developers.

Prestige, Sobha, Brigade and Godrej Properties were among the top gainers

In this briefing: Dabur India Ltd (DABUR IN) Q2FY26 Earnings Preview - Pharma & Healthcare Axis Punch: Star Cement - 8 Th October, 2025 Q2FY26 Earnings Preview - Automobile Sobha: On Track for a Record Year. Maintain BUY 1. Dabur India Ltd (DABUR IN) Dabur India Ltd (DABUR IN) 's business is contracting in volume and value, with declining margins, masking structural weakness through recurring excuses and shifting narratives across seasons and quarters. Disclosure standards have been reduced; management hides key metrics citing competitive sensitivity, obscuring true demand, volume trends, and domestic business performance. Q2 guidance cut to mid-single-digit growth confirms prior double-digit guidance was untenable, exposing weak underlying demand and the markets slow recognition of systemic underperformance. 2. Q2FY26 Earnings Preview - Pharma & Healthcare Pharmaceuticals: We expect pharmaceutical companies under our coverage to deliver a steady performance in Q2FY26, with aggregate revenue rising by 7.4% YoY and 2.7% QoQ to Rs 36,683 Cr.

In this briefing: Q2FY26 Earnings Preview - Pharma & Healthcare Axis Punch: Star Cement - 8 Th October, 2025 Q2FY26 Earnings Preview - Automobile Sobha: On Track for a Record Year. Maintain BUY From Tax Tailwind to Volume Surge: Bikajis Next Growth Phase 1. Q2FY26 Earnings Preview - Pharma & Healthcare Pharmaceuticals: We expect pharmaceutical companies under our coverage to deliver a steady performance in Q2FY26, with aggregate revenue rising by 7.4% YoY and 2.7% QoQ to Rs 36,683 Cr. EBITDA is estimated to increase by 7.5% YoY and 0.4% QoQ to Rs 8,510 Cr, while adjusted PAT is likely to grow by 10.2% YoY but decline 1.8% sequentially to Rs 5,014 Cr. The sectors operating margin is expected to remain stable at around 23.2%, supported by cost efficiencies and a favourable product mix despite continued pricing headwinds. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.